Pharmaceuticals News 17 October 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Stock Performance and Recent Moves Eli Lilly (NYSE: LLY) has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on

23 October 2025

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

SCNX Stock Soars on Arbli Launch News Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers

23 October 2025

FDA Approvals · Investment News · Market Trends · Pharmaceuticals · Stock Market

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes Buyout Sparks Rally in AVDL Stock On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right (CVR) tied to an FDA approval for idiopathic hypersomnia, valuing the deal

22 October 2025

Financial News · Investment Analysis · Mergers & Acquisitions · NASDAQ:ALKS · NASDAQ:AVDL · NASDAQ:JAZZ · Pharmaceuticals · Stock Market

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair Helge Lund and six other independent directors. A

22 October 2025

Business Rivalry · Corporate News · NYSE:NVO · Pharmaceuticals · Stock Market · Weight Loss

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight marketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped

21 October 2025

Biotech · Investment · Pharmaceuticals · Schizophrenia · Stock Market

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share marketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on

21 October 2025

Analyst Ratings · Biotech · Obesity Research · Pharmaceuticals · Stock News

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading volume is light (hundreds of thousands of shares),

21 October 2025

Biotechnology · Investing · Medical News · NASDAQ:SPRO · NYSE:GSK · Pharmaceuticals · Stock Market

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Stock Soars on Oct 20 Amid Wild October Trading Recursion’s stock is on a rollercoaster ride this month. Early on October 20, RXRX surged ~16–18%, hitting intraday highs near $6.8 benzinga.com. The rally comes after shares slid 7.9% on Friday

20 October 2025

Artificial Intelligence · Investing · Market News · Pharmaceuticals · Stocks

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Stock Price & Recent Performance Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior

19 October 2025

Business News · Investment · Market Analysis · NASDAQ:MTSR · NYSE:PFE · Pharmaceuticals · Stocks

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche reuters.com)

18 October 2025

Biotech News · Company Collaborations · Investment Analysis · NASDAQ:RANI · Pharmaceuticals · Stock Market

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2%

18 October 2025

Biotechnology · Healthcare · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market

XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Stock Price Skyrockets on Acquisition News Shares of XORTX Therapeutics Inc. (NASDAQ: XRTX) surged on October 17, 2025 after the nano-cap biotech announced a strategic acquisition in its core therapeutic area. The stock rocketed up immediately following the morning

17 October 2025

Business Deals · Kidney Health · Market Outlook · NASDAQ:XRTX · Pharmaceuticals · Stock News

Pharmaceuticals News 17 October 2025 - 23 October 2025